Navigation Links
NCX in Medical Technology

NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan

SOPHIA ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today provided an update on the phase 2a study for NCX 1000, which is covered by its codevelopment agreement with Axcan Pharma Inc. A preliminary analysis of 11 patients from this proof-of-concept study in...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

...se 2 proof-of-concept study for TPI 1020 (formerly ncx 1020) in Chronic Obstructive Pulmonary Disease (CO...ca and an option to obtain rest of world rights. ncx 4016 ncx 4016 is a nitric oxide-donating derivative of acet...

NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer I...

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...

NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology

... focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...

NicOx' Naproxcinod ABPM Data Presented at American Heart Association

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...

NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology

...res, Argentina. These included phase 1 results for ncx 1022, a prototype compound, showing the potential ...edical services. Furthermore, the clinical data on ncx 1022 suggest that nitric oxide donation may also i...owing encouraging results from a phase 1 study for ncx 1022, a lower potency prototype (see top-line resu...

NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...
NCX in Biological News

Biophysical Society announces 2008 International Travel Awards

...omputational Model of Ventricular Tissue. Carlo Manno, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela, Importance of ncx in the Regulation of Ca2+ Homeostasis in Skeletal Muscle. Maria V. Mernea, University of Bucharest, Romania, A Three-Dimensional Model of Epit...
NCX in Biological Technology

NicOx to Present at Financial Conferences in New York on November 27, 28 and 29

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer I...

NicOx Opens U.S. Headquarters in New Jersey

... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...
Other Tags
(Date:7/30/2015)... ... July 30, 2015 , ... Well-known San ... the largest, family-owned low cost service and repair companies. For 35 years, they ... as growing their company to meet the demands of the changing technological environment. ...
(Date:7/30/2015)... County, CA (PRWEB) , ... July 30, 2015 ... ... home health care throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today ... as the new Palliative Care Administrator. Dr. Demoratz is a strong proponent of ...
(Date:7/30/2015)... Beach, CA (PRWEB) , ... ... ... Center recently released a video, “Beachside Nursing Center,” to announce its position ... and five-star ratings. Beachside's administrator and staff members support the CMS rating ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Program and fourth annual Institute Scholar Program. In partnership with Patient Experience Institute, ... patient experience, develop leaders on the front lines and throughout the experience movement, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ross A. Clevens, MD, FACS ... as Assistant Professor of Plastic Surgery. This is Dr. Clevens’ second appointment by ... with the university, developing a strong presence and a valuable mentoring program for medical ...
Breaking Medicine News(10 mins):Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:Beachside Nursing Center Releases New Video 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
Other Contents